AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. The drug has gone on to become a huge success, generating sales of nearly $1.8 billion in 2020 alone as part of… Read More »AZ aims at Pfizer, GSK with potential new PARP cancer drug
With two cancer programs already making progress, Repertoire Immune Medicines will use the Series B financing to expand its immune synapse research to autoimmune disorders and infectious disease. CEO John Cox said his startup’s approach could advance immune medicines beyond the scope of currently available… Read More »Biotech startup Repertoire adds $189M to expand array of immune medicines
What does the world’s leading authority on carcinogens have to say about mobile phones? Do cell phones cause cancer? That’s a question billions of people would like to have answered and one I address in my video Cell Phone Brain Tumor Risk?. That’s why we… Read More »Do Cell Phones Cause Brain Tumors?
Sanofi, which already has messenger RNA R&D alliances with other companies, paid $160 million up front to acquire preclinical startup Tidal Therapeutics. The pharma giant said Tidal’s mRNA approach could lead to an off-the-shelf CAR-T therapy.
What You Should Know: – Philips and Ibex Medical Analytics announced a strategic partnership to globally commercialize clinically proven, AI-powered digital pathology solutions. The collaboration further cements Philips’ commitment to integrated diagnostics providing a clear path to precision diagnosis. – The trend towards centralized pathology labs, the… Read More »Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption
Do mobile phones cause brain tumors? Whenever a trillion-dollar industry is involved—whether it’s Big Food, Big Tobacco, Big Pharma, or Big Telecom—there’s so much money that the science can get manipulated. When it comes to the potential human health effects of cell phone use, certainly,… Read More »Can Cell Phone Radiation Damage Your DNA?
What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced… Read More »Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching
That is the title of a paper I just published at Value in Health with Suepattra G. May, Lauren M. Zhao, Katalin Bognar, Yong Yuan, John R. Penrod, and John A. Romley. The subtitle is A Stated Preference Survey of Adults Diagnosed With and Without… Read More »Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases
For those with recurrent canker sores, is it better to use a toothpaste with SLS, CAPB, or no foaming agents at all? Sodium lauryl sulfate (SLS) had already been used as a foaming agent in toothpastes for more than a half-century by the time a… Read More »Is Cocamidopropyl Betaine in Toothpaste Better Than Sodium Lauryl Sulfate?
Shots: The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum, BC, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Mabxience’s MB02 to be marketed as… Read More »mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer
Just because the sodium lauryl sulfate in toothpaste doesn’t cause cancer doesn’t mean it can’t cause problems. Sodium lauryl sulfate (SLS) is a common detergent used in toothpaste. It was featured in a famous Internet hoax nearly 20 years ago. Colgate toothpaste contains SLS, which… Read More »Is Sodium Lauryl Sulfate (SLS) in Toothpaste Safe?
Birju Shah, Head of Product for Uber Health & Communities Nick Jordan, Founder and CEO, Narrative In a world where technology and Big Data can provide us with instantaneous access to our banking transactions, and our financial information and credit reports can be retrieved with a… Read More »COVID Exposed The Dire Need for Real-Time Healthcare Data Sharing
The sulforaphane found in five cents’ worth of broccoli sprouts has been shown to benefit autism in a way no drug ever has in a randomized, double-blind, placebo-controlled study. You may remember my series of videos, which includes Prevent Cancer from Going on TOR, about… Read More »Helpful Foods to Support People with Autism
Linda Heim knew her dad didn’t plan to wait for the cancer to kill him. For decades, he’d lived in Montana, which they’d thought was one of the few places where terminally ill people could get a prescription to end their life. This story also… Read More »Getting a Prescription to Die Remains Tricky Even as Aid-in-Dying Bills Gain Momentum
What You Should Know: – Omega Healthcare, a provider of outsourced revenue cycle management and other healthcare support services, today announced the acquisition of himagine Solutions, a St. Louis based provider of medical coding and registry services. The transaction expands the service capabilities and geographical footprint of both companies, enhancing… Read More »Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model
The FDA has approved a Bristol Myers Squibb cell therapy made by engineering a patient’s immune cells to target a cancer protein called BCMA. The regulatory decision for Abecma in multiple myeloma gives BMS its second approved CAR-T therapy.
He was a top executive at Memorial Sloan Kettering before resigning over payments from health care companies. He went on to lead cancer research at AstraZeneca.
Dr. Miller, Medical Director of CancerLinQ LLC Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — like institutional racism and poverty — are a reflection of our broader society. Other inequities may go unrecognized but are… Read More »To Advance Health Equity, Put Real-World Cancer Data to Work
He was a top executive at Memorial Sloan Kettering before resigning over payments from health care companies. He went on to lead cancer research at AstraZeneca.
He was a top executive at Memorial Sloan Kettering before resigning over payments from health care companies. He went on to lead cancer research at AstraZeneca.
The world’s largest database of cancer mutations can now be used to link mutations with drug treatments in what promises to be a step forward in precision oncology. The COSMIC (Catalogue of Somatic Mutations in Cancer) database, operated by the Wellcome Sanger Institute, grew out… Read More »COSMIC database matches drugs to cancer mutations
There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the UK’s pharma industry. The Association of the British Pharmaceutical Industry (ABPI) report said that the UK must be more ambitious… Read More »Cancer services should be rebuilt after COVID disruption, experts say
What You Should Know: – NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35… Read More »NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M
Instil Bio, one of several companies developing tumor-infiltrating lymphocytes, will use its IPO cash to advance its clinical testing plans. Meanwhile, Finch Therapeutics and Gain Therapeutics also priced IPOs to fund clinical trials.
Aktis Oncology is developing cancer radiation treatments intended to more precise and potent compared to other radiotherapies. The startup is now out of stealth with $72 million in Series A financing.
Upcoming oncology trial? Which oncology eCOA Package offers the best ability to capture reliable endpoint evidence to increase speed, reduce cost, and ensure consistency across sites and geographies in less time? Find out. Consider these data points: 334 studies 158,000+ patients 67 countries 44,000+ sites… Read More »How do you get all the data quality benefits of eCOA in less time and at lower cost?
What happened when turmeric curcumin was put to the test to see if it could reverse DNA damage caused by arsenic exposure? Arsenic is a carcinogenic heavy metal, and the major mechanism of arsenic-related damage appears to be oxidative stress. It’s the arsenic-induced accumulation of… Read More »Benefits of Turmeric for Arsenic Exposure
Dr. Keith Kosel, Vice President at Parkland Center for Clinical Innovation (PCCI) “Show me the money!” No one old enough to have seen the 1996 movie, Jerry Maguire, will ever forget that memorable phrase. That simple but powerful phrase could apply to every person who… Read More »Achieving Financial Sustainability: A Connected Community of Care’s #1 Goal
In two pivotal studies years apart, Aveo Oncology’s drug tivozanib did not help kidney cancer patients live longer overall compared to the standard of care. The FDA approved still approved it, the latest development in a long saga that includes several regulatory stumbles.
Might lectins help explain why those who eat more beans and whole grains have less cancer? Lectins are to blame for the great “white kidney bean incident” of 2006 in Japan. One Saturday evening, a TV program introduced a new method to lose weight. The… Read More »Are Lectins in Food Good or Bad for You?
Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace. San Francisco-based Maverick’s technology is designed to target solid tumours with a T-cell attack that focuses… Read More »Takeda buys Maverick as T-Cell engager research hots up
How should we properly cook beans? In the 1800s, a compound was discovered in castor beans, which we would come to know as the first of a class of lectin proteins, natural compounds found throughout the food supply, but concentrated in beans, whole grains, and… Read More »How to Avoid Lectin Poisoning
Roche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that have failed to live up to their early promise. The Swiss pharma said it is voluntarily withdrawing the US indication for the immunotherapy Tecentriq (atezolizumab) in metastatic… Read More »Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues
Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work out. Already approved for auto-inflammatory diseases such as active systemic juvenile idiopathic arthritis under the brand name Ilaris, Novartis is… Read More »Novartis’ canakinumab falls short in phase 3 lung cancer trial
Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very… Read More »The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy
Shots: The company reported the voluntary withdrawal of the Tecentriq (atezolizumab) indication in the US for prior-platinum treated mUC, bladder cancer The withdrawal was made in consultation with the US FDA to review the accelerated approvals with confirmatory trials that have not met 1EPs and… Read More »Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US
BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials
What You Should Know: –BioIntelliSense announced it has entered into a strategic partnership with The Leukemia & Lymphoma Society (LLS) to incorporate the BioSticker™ platform in clinical trials of hematological cancer patients. – The LLS clinical trials will include use of the BioSticker medical device… Read More »BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials
Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and… Read More »Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease
Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported promising phase 2 trial results from bemarituzumab in November. The phase 2 FIGHT trial testing… Read More »Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug
Shots: Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021 The acquisition will expand Agilent’s capabilities in NGS-based cancer diagnostics and strengthen its position in precision oncology testing globally The… Read More »Agilent to Acquire Resolution Bioscience for $695M
A book purported to expose “hidden dangers” in healthy foods doesn’t even pass the whiff test. I started getting emails about The Plant Paradox, a book purporting to expose “the hidden dangers in ‘healthy’ foods that cause disease and weight gain”—foods like beans, whole grains,… Read More »Dr. Gundry’s The Plant Paradox Is Wrong
In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.
Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing data. Keytruda had been granted accelerated approval in metastatic small cell lung cancer (SCLC) with… Read More »Merck & Co axes Keytruda lung cancer niche amid FDA crackdown
With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age. Gov. Ned Lamont pointed to statistics… Read More »Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since… Read More »NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali
Vividion Therapeutics has technology that enables it to develop drugs for “undruggable” disease targets. The Series C financing is a crossover round, an indication a biotech is preparing for an IPO.
The FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease (GVHD), which cannot be treated with steroids. The US pharma, which has partnered with Novartis to develop this first-in-class JAK1/JAK2 inhibitor, said the FDA will review data… Read More »FDA to quickly review Incyte’s Jakafi in chronic GVHD
Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer, in non-small cell lung cancer patients whose tumours have high PD-L1 expression brings the drug into competition with… Read More »Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer
There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report. The report from European Federation of Pharmaceutical Industries and Associations (EFPIA) shows the results of research conducted in 2020… Read More »Limited access to cancer biomarker testing in Europe, report finds
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
AstraZeneca is withdrawing U.S. marketing of Imfinzi in bladder cancer after the drug failed a study required as a condition of its 2017 accelerated approval. The drug’s other approvals in lung cancer are not affected.
Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. That’s the view of analysts… Read More »Zynteglo halt re-ignites viral vector safety concerns; analysts
AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US. AZ’s share price ticked downwards after the announcement that it will stop marketing Imfinzi, a PD-L1 class immunotherapy, for previously treated adult patients… Read More »AZ withdraws Imfinzi in US bladder cancer use after trial failure
Ozette applies artificial intelligence to immune monitoring to gain greater insight into a cancer patient’s immune system. Beyond informing treatment decisions, the technology can guide drug and diagnostic development.
Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend. To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced… Read More »Astellas/Seagen prepare full US filing of bladder cancer drug Padcev
Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected… Read More »BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer
Phase 2 testing of Cyteir’s lead cancer drug candidate later is slated to start later this year. The Series C round of funding includes crossover investors, whose involvement is a sign a biotech is preparing for an IPO.
Is the exaggerated reaction of many Crohn’s disease patients to baker’s, brewer’s, and nutritional yeast just a consequence of their inflamed leaky gut, or might the yeast be a contributing cause? “Baker’s Yeast in Crohn’s Disease—Can It Kill You?” is the inflammatory title (no pun… Read More »Does Nutritional Yeast Trigger Crohn’s Disease?
Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients with recurrent or metastatic cervical cancer. The companies are asking for an accelerated approval based on phase 2 data, which will have to be confirmed by data… Read More »Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer
Minal Patel, CEO of Abacus Insights Laurent Rotival, SVP, Strategic Technology Solutions & CIO, Cambia Solutions We are all frustrated when there’s a glitch with our online banking, or if bandwidth problems interfere with streaming the movie we want to watch. Imagine how individuals will… Read More »Health Plans Must Go Beyond the ONC Mandate and Prioritize Member Experience
MEDSIR, a global company dedicated to independent clinical research in oncology, has initiated the PHERGain II clinical trial to demonstrate that in patients with HER2-positive early breast cancer with a good prognosis, a chemotherapy-free therapeutic approach can be as effective as the current standard of… Read More »A study to avoid chemotherapy in patients with early HER-2+ breast cancer
Warren A Whyte, Ph.D., VP Scientific Partnerships at ConcertAI According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more… Read More »Why Cancer Registries are Part of America’s Fight for Racial Equality
When her gynecologist recommended genetic testing, Mai Tran was reluctant. “I didn’t really want to do it,” recalled Tran, who had just turned 21 and was living in New York City, “but she kept on emailing me about it and was really adamant that I… Read More »Gene Screenings Hold Disease Clues, but Unexplained Anomalies Often Raise Fears
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the third CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
Walgreens appoints Rosalind (Roz) Brewer as the company’s Chief Executive Officer, effective on March 15, 2021. Brewer will also join the WBA Board of Directors upon assuming the role. She succeeds Stefano Pessina who, as previously announced, will transition to the role of Executive Chairman… Read More »Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others
Sana Biotechnology is turning new science into novel medicines intended to overcome limitations of current cell therapies. After going from stealth to IPO in two years, it’s now planning to bring multiple programs into clinical testing in 2022.
Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer for early stage, localized, watch-and-wait cancer. What about for more advanced stage life-threatening disease? Dr. Dean Ornish showed that a plant-based diet and lifestyle program could… Read More »Treating Advanced Prostate Cancer with Diet
In the final hours of the previous Administration’s time in office, the Center for Medicare & Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing five-year Part D Payment Modernization Model. This model would provide “formulary flexibility” by exempting… Read More »Action needed to preserve the six protected classes
Chris Evanguelidi, Director, Enterprise Healthcare Market for Redpoint Global Inc. Researchers from Johns Hopkins published a study in October on the impact of the pandemic on health care delivery. Among its findings, the data show a 21.4% decrease in primary care visits in Q2 of… Read More »A Patient Engagement Strategy Needs to Deliver a Holistic Experience
What You Should Know: – Syapse raises 68M in equity investment led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence through Syapse’s Learning Health Network. – The Syapse Learning Health Network is a global precision oncology data sharing network,… Read More »Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network
What You Should Know: – Volpara Health, an integrated breast care platform assisting in the delivery of personalized patient care has acquired breast cancer risk assessment platform CRA Health. – CRA Health, LLC, is a breast cancer risk assessment company spinoff from Massachusetts General Hospital… Read More »Volpara Acquires Breast Cancer Risk Assessment Platform CRA Health for $18M
Check out news from healthcare startups including Carrum Health, Seven Bridges Genomics, Outcomes4Me and more.
AstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as part of their ongoing partnership. Results announced at the World Conference on Lung Cancer came from Enhertu (trastuzumab deruxtecan), which targets cancers expressing the HER2 receptor and… Read More »AZ/Daiichi Sankyo’s partnership makes progress in lung cancer
The effects of coconut oil were compared to butter and tallow. Even if virgin coconut oil and other saturated fats raise LDL “bad” cholesterol, isn’t that countered by the increase in HDL “good” cholesterol? According to “the experience and wisdom of 200 of the country’s… Read More »Coconut Oil and the Boost in HDL “Good” Cholesterol
As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines’ appropriateness for older adults with various illnesses. Among them are cancer patients receiving active treatment, dementia patients near the end of their lives and people with autoimmune conditions. Recently, a… Read More »If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?
Governments must act to restore the damage done to lung cancer services during the pandemic in order to reduce further avoidable deaths, according to a report drawn up as part of this week’s World Economic Forum in Davos. The report, Learning Lessons from Across Europe… Read More »Pandemic ‘pushed lung cancer services back 20 years’, doctors warn
Digital cancer care platform Careology has joined forces with RedArc, which provides long-term support for people with serious illnesses. RedArc has a team of registered nurses that provide support and expert advice by phone to people after referral from insurers, trade unions and groups such… Read More »Careology joins forces with remote care support firm RedArc
Ed Simcox, Chief Strategy Officer at LifeOmic The COVID-19 pandemic, which has taken 270,000 American lives to date, has shined a light on another crisis — the U.S. currently has no standardized system for reporting public health data. Health departments all over the country resort… Read More »To Beat COVID-19, We Need A Modern Approach to Public Health Data
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer cases and deaths that will occur in the United States. For… Read More »ICYMI: Cancer death rate continues decline due to advances in treatment
Are there unique benefits to brown rice that would justify keeping it in our diet despite the arsenic content? For years, warnings had been given about the arsenic levels in U.S. rice potentially increasing cancer risk, but it had never been put to the test… Read More »Do the Pros of Brown Rice Outweigh the Cons of Arsenic?
AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab). This latest indication adds to Enhertu first approval at the end of 2019 for advanced HER2-positive breast cancer after… Read More »AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
A former Merck & Co scientist could face up to 10 years in prison after he was accused of stealing trade secrets relating to drugs including the cancer immunotherapy Keytruda by US authorities. In a document outlining the charges against Shafat Quadri, of North Potomac,… Read More »Ex-Merck & Co scientist accused of stealing trade secrets could face jail
What You Should Know: – FCC announces initial 14 pilot project selected for $100M Connected Care Pilot Program that will support connected care service across the country and focus on low-income and veteran patients. The Federal Communications Commission (FCC) today announced an initial set of… Read More »FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program
Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance. Zejula competes with AstraZeneca/Merck & Co’s PARP inhibitor class rival Lynparza (olaparib) but in this case it has an advantage… Read More »NICE recommends interim funding for GSK’s Zejula in ovarian cancer
Arsenic is not just considered to be a carcinogen; it’s also designated as a “nonthreshold carcinogen, meaning that any dose, no matter how small, carries some cancer risk”—so there really isn’t a “safe” level of exposure. Given that, it may be reasonable to “use the… Read More »Is White Rice a Yellow-Light or Red-Light Food?
Last year, I published a paper that showed that cancer mortality rates fell by 24% between 2000 and 2016 and further that new cancer drugs accounted for saving 1.3 million lives in the US over that time period. At the end of the paper, we… Read More »Large decline in cancer mortality
Host response can be identified by proteomic profiling, which involves analyzing a broad range of select proteins in a series of patient blood samples, with the first collected prior to treatment and the next collected after the first dose of treatment
Boehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight cancer using “dark antigens” in a deal worth up to €876 million ($1.07bn). Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic… Read More »Boehringer to investigate ‘dark antigens’ with UK cancer specialist Enara
What are some strategies to reduce arsenic exposure from rice? Those who are exposed to the most arsenic in rice are those who are exposed to the most rice, like people who are eating plant-based, gluten-free, or dairy-free. So, at-risk populations are not just infants… Read More »How Much Arsenic in Rice Is Too Much?
Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off
Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by… Read More »Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off
Shots: The companies collaborated to evaluate the use of immunoSEQ T-MAP, for which Adaptive will receive quarterly payments + sequencing and data mapping fees AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical… Read More »AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer
What You Should Know: – COVID-19 care deferrals lead to three major boomerang conditions that payers and providers must proactively address in 2021, according to a newly released report by Prealize. – COVID-19’s hidden victims—those who avoided or deferred care during the pandemic—will increasingly return… Read More »COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021
Getting rice down to the so-called safe water limit for arsenic would still allow for roughly 500 times greater cancer risk than is normally considered acceptable. Given the level of arsenic in rice, how could we figure out how much rice is too much? There… Read More »How Risky Is the Arsenic in Rice?
ImaginAb has signed a deal with Pfizer, which it hopes will help it to gather information necessary for approval of its tumour imaging agent as a medical device in markets in the US and other countries. The California-based company has signed a non-exclusive license with… Read More »Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech
Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work This thought leadership series has been paid and developed by Kite,… Read More »Why cell therapy manufacture is a team sport
Assaf Halevy, Founder and CEO of 2bPrecise Electronic medical records (EMRs) are widely expected to serve as a cornerstone technology that drives the delivery of modern patient care. But can the EMR alone support all the informatics capabilities required by an ever-evolving healthcare industry? The… Read More »Meaningful Use of Genomics Requires Informatics Beyond EMRs
What You Should Know: – RenalytixAI and DaVita announce a program partnership that aims to slow kidney disease progression and improve outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). – This is the first clinical-grade program that delivers advanced early-stage… Read More »DaVita & RenalytixAI Partner for Early Risk Identification to Help Slow Kidney Disease Progression
Teladoc Health and Livongo Merge The combination of Teladoc Health and Livongo creates a global leader in consumer-centered virtual care. The combined company is positioned to execute quantified opportunities to drive revenue synergies of $100 million by the end of the second year following the… Read More »2020’s Top 20 Digital Health M&A Deals Totaled $50B
I recommend people switch away from using rice milk For kids and teens, the amount of arsenic flowing through their bodies was found to be about 15 percent higher for each quarter cup of rice consumed per day, and a similar link was found in… Read More »Arsenic in Rice Milk, Rice Krispies, and Brown Rice Syrup
Donovan Quill, President and CEO, Optime Care Industry experts state that orphan drugs will be a major trend to watch in the years ahead, accounting for almost 40% of the Food and Drug Administration approvals this year. This market has become more competitive in the past few years,… Read More »Patient-First Model: High Tech Meets High Touch for Individuals with Rare Disorders
When it comes to rice and rice-based products, pediatric nutrition authorities have recommended that arsenic intake should be as low as possible. “The US Food and Drug Administration (FDA) has been monitoring the arsenic content in foods” for decades, yet despite the “well-established science describing… Read More »Arsenic in Infant Rice Cereal
Bristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of brain cancer, saying that it looks unlikely to produce a survival benefit in the disease. BMS said an independent committee had reviewed data from the phase 3… Read More »BMS calls time on brain cancer trial as Opdivo misses second target
Boiling rice like pasta reduces arsenic levels, but how much nutrition is lost? Cooking rice in a high water-to-rice ratio reduces toxic arsenic content, which I discuss in my video How to Cook Rice to Lower Arsenic Levels. What exactly does that mean? Well, as… Read More »How to Cook Rice to Lower Arsenic Levels
Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial
Servier Acquires Agios’ Cancer Portfolio in a USD 2 Billion Deal The year is a prime witness of pricey deals and acquisitions in the pharmaceutical industry. To leave its mark, another player decided to hop onto the list. French drugmaker Servier has announced the acquisition… Read More »Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial
AstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its use to a group of patients with early-stage disease. The new use covers adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell… Read More »AZ’s Tagrisso gets new early lung cancer use in US
MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data gathered so far in advanced disease. Margenza (margetuximab) won FDA approval in combination with chemotherapy to treat metastatic… Read More »MacroGenics’ HER2 breast cancer drug Margenza approved in US
Amgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer patients with an aggressive form of the disease. The drug was the first targeted at the mutation known as KRAS to show activity in the clinic and… Read More »Amgen files KRAS trailblazer sotorasib with FDA for lung cancer
That is the topic of a commentary I wrote with co-authors Joanna MacEwan and Farzad Ali, titled “Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?” An excerpt is below: Cancer mortality rates have fallen significantly over… Read More »COVID-19 and Reductions in Cancer Mortality
Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. The demand for skilled nurses during the pandemic is through the roof! Travel nurses command a hefty salary and they… Read More »Readers and Tweeters Defend Front-Line Nurses and Blind Us With Science
Brown rice contains more arsenic than white rice, but the arsenic in brown rice is less absorbable, so how does it wash out when you compare the urine arsenic levels of white-rice eaters to brown-rice eaters? Arsenic in rice is a cause for concern, according… Read More »Which Rice Has the Least Amount of Arsenic: Black, Brown, Red, White, or Wild?
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific cancer types. Since peaking in 1991, the death rate associated with cancer declined by… Read More »Report: More than 1,300 medicines and vaccines in development to help fight cancer
Shots: Roche launches the cobas PIK3CA mutation test for patients with advanced/ m-BC in countries accepting the CE mark The IVT test is a real-time PCR test for the qualitative detection & identification of 17 mutations in exons 2, 5, 8, 10 & 21 in… Read More »Roche Launches Cobas PIK3CA Mutation Test for Patients with Advanced or Metastatic Breast Cancer
Some of the biggest legal stories of the year include patients attempting to mount a class action lawsuit against Mayo Clinic after an employee improperly viewed more than 1,600 health records and the Supreme Court hearing opening arguments in a case challenging the constitutionality of… Read More »5 big healthcare lawsuits of 2020
Daiichi Sankyo and AZ’s Trastuzumab Deruxtecan Receives CHMP’s Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer
Shots: The recommendation is based on a P-II DESTINY-Breast01 study assessing trastuzumab deruxtecan in patients with HER2 positive unresectable/ m-BC prior treated with trastuzumab emtansine The trial demonstrated a meaningful & durable activity in patients who had received two or more prior anti-HER2 therapies. The… Read More »Daiichi Sankyo and AZ’s Trastuzumab Deruxtecan Receives CHMP’s Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer
What You Should Know: – LeanTaaS raises $130 million in Series D Funding to strengthen its machine learning platform to continue helping hospitals achieve operational excellence during a time where they are facing mounting financial pressures due to COVID-19. – LeanTaaS provides software solutions that… Read More »LeenTaaS Secures $130M for ML Platform to Help Hospitals Achieve Operational Excellence
What You Should Know: – San Francisco-based digital health startup Pair Team emerges out of stealth with $2.7M in seed funding backed by Kleiner Perkins, Craft Ventures, & YC. – Pair Team provides both a remote team and AI that automates workflows, provides infrastructure &… Read More »Pair Team Emerges Out of Stealth with $2.7M to Automate Primary Care Operations
COVID-19’s knock-on effect on cancer patients is of concern by HCPs, with delayed or decreased diagnosis seen as a key worry. CREATION.co’s Lara Meyer explores why HCPs need more support. The COVID-19 pandemic has been mainstream headline news throughout 2020 and continues to have a… Read More »What HCPs think about COVID-19’s impact on cancer
A daily half-cup of cooked rice may carry a hundred times the acceptable cancer risk of arsenic. What about seaweed from the coast of Maine? “At one point during the reign of King Cotton, farmers in the south central United States controlled boll weevils with… Read More »Cancer Risk from Arsenic in Rice and Seaweed
The FDA has placed a clinical hold on a phase 1/2 trial of Bellicum’s cancer cell therapy BPX-601, following a patient death. Houston, Texas-based Bellicum said that the regulator had placed recruitment and dosing on hold in the dose-escalation trial in patients with previously treated… Read More »FDA puts Bellicum’s cancer cell therapy trial on hold
Read news from healthcare startups Outcomes4Me, Specifica, Segmed, and more.
Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, with clinical trials expected to start next year. The California biotech had reached an agreement with Iconic and Zymeworks giving the option on the drug in May… Read More »Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC
Even at low-level exposure, arsenic is not just a class I carcinogen, but may also impair our immune function and increase our risk of cardiovascular disease and diabetes. When people hear about arsenic, they think of it as an acute poison, and, indeed, a tiny… Read More »The Effects of Too Much Arsenic in the Diet
Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer. The principle of DNA damage response is already being exploited by AstraZeneca and other companies with their poly (ADP-ribose) polymerase (PARP)… Read More »Merck KGaA signs DNA damage response cancer deal with Artios Pharma
Shalini Shah, MD is Vice-Chair and Associate Professor, Department of Anesthesiology & Perioperative Care, and Enterprise Director of Pain Services, UC Irvine Health The dominant presence of COVID-19 has not meant the absence of cancer, ear infections, heart attacks, chronic pain, or other illnesses that… Read More »Virtual Engagement During COVID Pushes Paradigm Shift for Physician Training and Patient Care
Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial. The drug is an antibody-drug conjugate where a monoclonal antibody is linked to monomethyl auristatin, a cancer-killing “payload”. It is targeted against AXL,… Read More »Genmab axes development of AXL-targeting cancer drug enapotamab vedotin
What was the National Chicken Council’s response to public health authorities calling for the industry to stop feeding arsenic-based drugs to poultry? “Dietary practices influence our exposure to pesticides, toxic heavy metals, persistent organic pollutants, and industrial pollutants….A diet high in fish and other animal products,… Read More »Why Was Chicken the Primary Source of Arsenic Exposure in Children?
Shots: The company has submitted an MAAA for BAT1706 to EMA. Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the EU Member States, Iceland, Norway, and Liechtenstein The submission of the MAA for BAT1706 marks it as the first ex-China MAA/… Read More »Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin
Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others
Neela Montgomery, EVP & President at CVS Pharmacy/Retail CVS Health Corporation names Neela Montgomery Executive Vice President and President of CVS Pharmacy/Retail, effective November 30, 2020. Montgomery will oversee the company’s 10,000 pharmacies across the United States. Montgomery, currently a Board Partner at venture capital… Read More »Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others
Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will… Read More »Novartis set to overcome $14 billion patent cliff say analysts
Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread. Just 48 and the mother of two teenagers, Baldeschwiler was diagnosed with stage 4 metastatic breast cancer after discovering… Read More »New Legal Push Aims to Speed Magic Mushrooms to Dying Patients
What You Should Know: – COTA, Inc., a healthcare technology company that uses real-world data to bring clarity to cancer care, has secured $34M in funding. – Access to over one million patient data records and additional funding support enhanced real-world data and analytics services… Read More »COTA Lands $34M to Drive Innovation in Oncology Using Real-World Data
What You Should Know: – Volaris Group acquires medaptus, a clinical workforce, and workflow solutions that empower healthcare delivery entities to achieve their desired patient, clinical and financial outcomes. Today, Volaris Group has acquired medaptus, a healthcare technology company that removes the administrative burden from… Read More »Volaris Group Acquires Clinical Workforce & Workflow Platform medaptus
Lead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule drugs for immune diseases. The deal will revolve around a single undisclosed drug target and will see the Dutch biotech receive 10 million euros up front from… Read More »Lead Pharma signs $308m deal to develop small molecule drugs with Roche
There are so many açaí products on the market now, from frozen pulp in smoothie packs to freeze-dried powder and supplements. How is it eaten traditionally? “In the Brazilian Amazon, the Indian tribes of the forest cut down the tree and eat the palm heart…then… Read More »The Antioxidant Power of Açaí vs. Apples
Holders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out after the company said COVID-19 travel restrictions are delaying a key regulatory review. Shareholders in Celgene received a contingent value right (CVR) at the time of the… Read More »Fresh doubts over BMS’ merger payout as FDA delays key drug review
The cancer and cardiovascular care provider has teamed up with GE Healthcare, granting its 440 centers in the U.S., U.K., Spain and Australia access to GE equipment and services. The organizations will also explore research opportunities.
CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors… Read More »German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy
Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated patients. Keytruda (pembrolizumab) and Lenvima (lenvatinib) outperformed standard care – Pfizer’s Sutent (sunitinib) –… Read More »Merck & Co/Eisai eye kidney cancer use for immunotherapy combination
What You Should Know: – RxVantage has acquired onPoint Oncology to provide cancer care teams with on-demand access to educational resources, reimbursement data, and analytics. – The acquisition of onPoint Oncology builds on RxVantage’s rapidly expanding digital offerings for providers. In April, RxVantage launched Virtual Meetings to help providers… Read More »M&A: RxVantage Acquires onPoint Oncology to Expand Offering to Oncology Practices
Previously treated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVie’s Venclyxto and Roche’s Gazyva. The decision by NICE allows for the 12-month fixed duration treatment option based on data… Read More »NICE backs chemo-free CLL combination from AbbVie and Roche
As I discuss in my video The Role of Soy Foods in Prostate Cancer Prevention and Treatment, a compilation of 13 observational studies on soy food consumption and the risk of prostate cancer found that soy foods appear to be “protective.” What are observational studies?… Read More »Can Soy Prevent and Treat Prostate Cancer?
That is the finding from a recent paper by myself and co-authors Joanna MacEwan, Syvart Dennen, Rebecca Kee, Farzad Ali, and Katharine Batt. An excerpt from the paper is below: Between 2000 and 2016, deaths per 100,000 population across the 15 most common tumor types… Read More »New cancer drugs saved 1.3 million lives
Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left… Read More »Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China
The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics. NICE has been assessing medicines for 21 years using the Quality Adjusted Life Year (QALY) – the cost to ‘buy’… Read More »After two decades, NICE begins consultation on drug assessment methods
Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion in cash. Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been… Read More »Merck & Co buys cancer biotech VelosBio for $2.75bn
AstraZeneca and MSD’s Lynparza (olaparib) Receive EU’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
Shots: The approval is based on a biomarker subgroup analysis of P-III PAOLA-1 study assessing Lynparza + bevacizumab vs bevacizumab alone as 1L maintenance treatment in patients with newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometrioid ovarian, fallopian tube, peritoneal cancer who had CR/PR to… Read More »AstraZeneca and MSD’s Lynparza (olaparib) Receive EU’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
As you can see at the start of my video Fermented or Unfermented Soy Foods for Prostate Cancer Prevention?, there is an enormous variation in the rates of prostate cancer around the globe, with among the highest rates in the United States and lowest rates… Read More »Fermented or Unfermented Soy?
After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is determined to put that experience to good use. The avid blogger and passionate advocate retired from his R&D role four years ago to focus on his own… Read More »Be in the room: Turning patient engagement to patient centricity
AstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely watched coronavirus vaccine trial. AZ said in its third quarter results statement that it is on track to meet its guidance for the year, with total revenue… Read More »AZ’s Q3 results disappoint – but COVID19 vaccine trial is still on track
What You Should Know: – The FDA just extended its research collaboration agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting cancer. – With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the… Read More »FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer
The European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients with the most common form of liver cancer. Tecentriq (atezolizumab) can be used with Avastin (bevacizumab) for adults with advanced or unresectable hepatocellular carcinoma (HCC) who have… Read More »Europe approves Roche’s Tecentriq liver cancer combination
Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer
Shots: The pivotal P-III MONALEESA-7 study assessing Kisqali + endocrine therapy vs PBO + endocrine therapy, in pre- & perimenopausal women with HR+/HER2- advanced or metastatic-BC The study met its 2EPs of OS, demonstrating a significant improvement in OS, and is consistent for the NSAI… Read More »Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer
Shares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy will likely fail to produce results in non-small cell lung cancer. Jounce was combining its vopratelimab with BMS’ already-approved Yervoy, hoping that the experimental drug will bolster… Read More »Jounce shares crash after it abandons immunotherapy combination trial
AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer
Shots: Fusion to receive up front, as well as development milestones and other payments. The companies will jointly discover, develop, and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing… Read More »AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer
Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million). The French pharma is buying Kiadis for 5.45 euros per share in cash, an offer price representing a premium of… Read More »Sanofi to acquire Kiadis and NK cell tech for $353 million
Shots: The approval is based on PRIMA study assessing Zejula (300mg qd), later amended to incorporate an individualised starting dose of Zejula (200 mg or 300 mg, qd) based on the patient’s baseline weight and/or platelet count Results: The PRIMA study improved PFS for patients… Read More »GSK’s Zejula (niraparib) Receives EC’s Approval as a Treatment in Advanced Ovarian Cancer
Liquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will be used to expand commercial opportunities. ANGLE’s Parsortix system detects and captures circulating tumour cells (CTCs) in blood for subsequent analysis. The company believes there is huge… Read More »ANGLE raises £20m, eyes opportunity in immunotherapy trials
At the start of my video What Does a Low White Blood Cell Count Mean?, you can see what it looks like when you take a drop of blood, smear it between two pieces of glass, and view at it under a microscope: a whole… Read More »What White Blood Cell Count Should We Shoot for?
Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and stock deal worth up to $2.15 billion, positioning it as a… Read More »Exact Sciences buys cancer detection company Thrive for $2.15 billion
Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase. No one gets through cancer unscathed. People are usually left with a mixture of treatment aftereffects, toxic positivity, and lingering anger to deal with.… Read More »Toxic positivity and grief: The reality of living through cancer
What You Should Know: – FDA awards AppliedVR Breakthrough Device designation for treating treatment-resistant fibromyalgia and chronic intractable lower back pain – AppliedVR’s EaseVRx program helps patients learn self-management skills grounded in evidence-based cognitive-behavioral therapy (CBT) principles and other behavioral methods. AppliedVR, a pioneer advancing… Read More »FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, according to a recent study published in Health Affairs. This underscores the crucial role of biopharmaceutical innovation, as life expectancy increased 3.3 years during that time period.
What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the… Read More »JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository
What You Should Know: – Today, Blue Cross and Blue Shield of North Carolina partners with Carrot Inc. and Virta Health to help address two of the largest ongoing health issues facing Americans today – smoking and type 2 diabetes. – Virta and Carrot’s programs… Read More »Blue Cross NC Launches No-Cost Virtual Programs to Quit Smoking and Reverse Diabetes
The years of healthy life lost due to our consumption of trans fats are comparable to the impact of conditions like meningitis, cervical cancer, and multiple sclerosis. But, if “food zealots” get their wish in banning added trans fats, what’s next? I explore this in… Read More »What About the Trans Fat in Animal Fat?
AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
Shots: AstraZeneca’s Tagrisso has received sNDA’s acceptance and has been granted PR in the US for the adjuvant treatment of patients with early-stage (IB, II, and IIIA) EGFRm NSCLC after complete tumor resection with curative intent The sNDA is based on the P-III ADAURA trial… Read More »AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung cancer. Results from the phase 3 ADAURA trial were the talk of this year’s American Society of Clinical Oncology (ASCO) conference in summer and the regulator has… Read More »FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancer
Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike in demand for COVID-19 tests spared the Swiss company’s blushes. Sales of its “big three” cancer drugs were all down considerably in Q3 as cheaper biosimilars gained… Read More »COVID-19 tests prop up Roche as US biosimilars bite in Q3
What You Should Know: – FUJIFILM Medical Systems U.S.A., Inc. and Volpara Solutions announced the extension of their partnership to provide mammography facilities and clinicians with breast imaging solutions designed to improve image quality, streamline workflow and accurately assess a patient’s breast density. – Building… Read More »Fujifilm & Volpara Partner to Help Clinicians Determine Patient Breast Density
Chemotherapy has been a powerful method for fighting cancer for decades. One of the most effective therapies available, it is also known for weakening the patient and causing harsh side effects like pain, nausea, and hair loss. This is because in its zeal to attack… Read More »Model-based Strategy to Guide the Choice of Clinical Doses for ADC
The company has received FDA approvals for two cancer drugs in less than 12 months and announced partnerships with Merck last month for a Phase II antibody-drug conjugate and a marketed drug.
Given the role that oxidant free radicals are thought to play in aging and disease, one reason fruits and vegetables may be so good for us is that they contain antioxidant compounds. As you can see at 0:20 in my video Benefits of Marjoram for… Read More »How to Treat Polycystic Ovary Syndrome (PCOS) with Diet
Cleveland Clinic’s top clinicians and researchers present the top 10 medical innovations transforming medical advancements and new awards to recognize healthcare innovation. The list of breakthrough technologies was selected by a committee of Cleveland Clinic subject matter experts, led by Will Morris, M.D., executive medical… Read More »Cleveland Clinic Names Top 10 Medical Innovations For 2021
What You Should Know: – Amazon Web Services (AWS) and the Pittsburgh Health Data Alliance (PHDA) announce a collaboration to produce more accurate machine learning models for breast cancer screening and depression. – In work funded through the PHDA-AWS collaboration, a research team led by… Read More »AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models
The FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation to approve from a panel of expert advisers. In August the FDA’s Oncology Drugs Advisory Committee voted nine to one in favour of approving Ryoncil (remestemcel-L), making… Read More »Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease
The findings may make it possible to identify a subset of patients who experience poorer outcomes or more serious side effects, especially neurotoxicity.
What You Should Know: – NVIDIA and Massachusetts General Brigham Hospital researchers develop an AI model that determines whether a person showing up in the emergency room with COVID-19 symptoms will need supplemental oxygen hours or even days after an initial exam. – The ultimate… Read More »NVIDIA Develops AI Model to Accurately Predict Oxygen Needs for COVID-19 Patients
New Jersey Urology What You Should Know: – New Jersey Urology (NJU) becomes the first urology-only group to launch a urologic-centric Epic electronic health record (EHR). – NJU is the largest urology practice providing complete urologic care and comprehensive individualized treatment at more than 60… Read More »New Jersey Urology Launches First-Ever Urologic-Centric Epic EHR
Bristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication for untreated mesothelioma, a rare but aggressive form of cancer that forms in the lining of the lungs. The FDA has approved Opdivo (nivolumab) and Yervoy (ipilimumab),… Read More »FDA approves BMS’ Opdivo and Yervoy combination in first-line mesothelioma
Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. The deal with the Oslo-based company is worth up to $715 million, with… Read More »Roche pays $200m for Vaccibody’s cancer vaccine drug
Ranitidine is a pharmaceutical drug that is categorized as a histamine antagonist, also called an H2 blocker, that has popularly been used to treat acid reflux. However, this medication had recently raised controversies when the Food and Drug Administration (FDA) announced a product recall of… Read More »6 Reasons Why Ranitidine Is Harmful and How It Caused Cancer to Many
Improving cognitive performance with aromatherapy in young, healthy volunteers is one thing, but how about where it really matters? As I discuss in my video Best Aromatherapy Herb for Alzheimer’s, a group of Japanese researchers had a pie-in-the-sky notion that certain smells could lead to… Read More »Topical Lemon Balm Lotion for Alzheimer’s
US representative Katie Porter used her now-signature whiteboard as she questioned former Celgene CEO Mark Alles over the connection between the significant price hike for Revlimid, a common cancer drug, and his personal bonus. The Democratic congresswoman for California presented her argument during a House oversight and… Read More »Katie Porter lambasts big pharma over cancer drug price hike using whiteboard calculations – video
What You Should Know: – physIQ has been selected by the National Institute of Health (NIH) to develop an innovative AI-based COVID-19 digital biomarker solution to address the COVID-19 pandemic. – Early detection of COVID-19 decompensation in patients is complicated by infrequent and non-specific clinical… Read More »NIH Taps PhysIQ to Develop AI-Based COVID-19 Digital Biomarker
“Nearly 20% of cancer cases arising worldwide can be linked to infectious agents, including viruses.” Seven viruses are now conclusively tied to human cancers, and, as new viruses enter into human populations, the incidence and causes of cancer will likely change accordingly. The foundation of… Read More »The Role of Meat and Dairy Viruses in Cancer
The company hopes to use the money to bring its T-cell antigen coupler cell therapy technology – currently in preclinical development – into human clinical trials. German drugmaker Bayer’s venture capital arm led the round.
The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical… Read More »TIGIT Therapies Digital Summit
Dr. Kayur Patel, Chief Medical Officer of Proactive MD The impact of the coronavirus crisis is shining a bright light on many of the challenges facing the U.S. healthcare system. So much more than a lack of primary care physicians and hospital beds, the all-hands-on-deck… Read More »The Coronavirus Crisis’ Silent Death Toll: Chronically Ill Patients
NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection. The new guidance recommends Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine, for adults with diffuse large B-cell lymphoma (DLBCL), in second line… Read More »NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy
The update to the partnership includes opt-in rights for Gilead on 15 drug targets, up from five under the original 2018 deal. Gilead will pay $125 million upfront and make a $20 million equity investment in Tango, which focuses on synthetic lethality.
What would happen if you secretly gave cancer patients four of the healthiest foods? In my video Pomegranate vs. Placebo for Prostate Cancer, I discussed how pomegranate pills appeared useless in the treatment for prostate cancer, and the same disappointing results were seen with a… Read More »Food Combining for Prostate Cancer
The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic visits for patients with lung and bladder cancer. The regulator has granted a faster six-month Priority Review for the fixed… Read More »AZ aims to cut cancer clinic visits with new Imfinzi regimen
Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of checkpoint inhibitor therapies, which work by flipping a biochemical switch on tumour cells… Read More »BMS signs $475m cancer immunotherapy deal with Dragonfly
What You Should Know: – CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer. – CancerIQ’s technology enables hospitals to use genomics to… Read More »CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
The Chicago-based startup company plans to use the funding to further growth of its product offering and integration with EHRs and genetic testing partners.
The reason egg consumption is associated with elevated cancer risk may be the TMAO, considered the “smoking gun” of microbiome-disease interactions. “We are walking communities comprised not only of a Homo sapiens host, but also of trillions of symbiotic commensal microorganisms within the gut and… Read More »What Explains the Egg-Cancer Connection
What You Should Know: The FDA and Syapse announce research collaboration expansion to address urgent public health challenges including supporting FDA’s goal of rapid understanding of COVID-19. As part of the research, Syapse is partnering with FDA’s Oncology Center of Excellence to investigate methods to… Read More »FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.
This content is password protected. To view it please enter your password below: Password:
When reviewing a return to normal operations, there is much to consider. Here are four approaches aimed at establishing a healthy pathway back to something close to the norm.
The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been approved in patients who have received at least four therapies including an anti-CD38 such as Darzalex, a proteasome inhibitor and… Read More »FDA approves GSK’s Blenrep for advanced multiple myeloma
Shaving before applying underarm antiperspirants can increase aluminum absorption. Could this explain the greater number of tumors and the disproportionate incidence of breast cancer in the upper outer quadrant of the breast near the armpit? A famous case report called “The Mortician’s Mystery,” published in… Read More »Armpit Shaving and Breast Cancer
What You Should Know: – Today, Talis Biomedical Corporation announced it has been awarded a $25M contract from the National Institutes of Health (NIH) as part of Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative as well as another $100 million in additional… Read More »Talis Awarded $25M NIH Contract for Point-of-Care COVID-19 Testing
Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome CAR-T therapy. At the beginning of the year Incyte paid $750m to Morphosys for the CD-19 targeting… Read More »Incyte/Morphosys take on CAR-Ts as lymphoma antibody Monjuvi approved in US
Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation, meaning Bayer’s class rival faces competition in Europe for the first time. Last September Bayer’s Vitrakvi became the first NTRK inhibitor class drug approved in Europe… Read More »Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europe
NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for NHS patients in England. The cost-effectiveness body okayed interim reimbursement from the Cancer Drugs Fund (CDF) in final guidance for… Read More »NICE backs kidney cancer combination from Merck KGaA and Pfizer
Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs. Product sales in Q2 were down nearly 10% compared with last year… Read More »Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition
Physical fitness authorities seem to have fallen into the same trap as the nutrition authorities, recommending what they think may be achievable, rather than simply informing us of what the science says and letting us make up our own minds. Researchers who accept grants from… Read More »What Exercise Authorities Don’t Tell You About Optimal Duration
Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast review from the FDA. BMS gave Celgene’s shareholders a “Contingent Value Right” (CVR) to sweeten the… Read More »BMS ‘bet’ with Celgene shareholders in balance after CAR-T refile
The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.
It may be more expedient politically to promote an increase in consumption of healthy items rather than a decrease in consumption of unhealthy items, but it may be far less effective. The World Health Organization has estimated that more than a million deaths “worldwide are… Read More »The Crowding Out Strategy to Eating Healthier
The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu.
Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of… Read More »Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer
Read about new developments from healthcare startups including HealCo, Eikonoklastes, Sidecar Health and more.
European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle cancers on the basis of the mutations they harbour, and has already had the drug approved by the FDA at… Read More »European regulators back Blueprint’s Ayvakyt for stomach tumours
A digital platform allowing clinicians to remotely monitor cancer patients’ health in real time has been launched in the UK. Already available on iOS with an Android version in the works, Careology Professional aims to give healthcare professionals a view of their patients’ health status… Read More »Careology launches digital platform to monitor cancer patient’s health
Roche has announced half-year results showing the COVID-19 pandemic affected sales of its key products, with currency headwinds also weighing on revenues. The Swiss pharma’s figures came shortly after its arch-rival Novartis conceded that it had hit similar problems as the pandemic meant fewer patients… Read More »Pandemic and currency headwinds hurt Roche in first half
Let’s catch on some non-coronavirus research today with an interesting approach against a very bad disease, metastatic colon cancer. This new paper (from groups at Virginia Tech and Wake Forest) adds to our understanding of something that’s been noticed for some time: colon cancer tissue… Read More »Bacteria and Colon Cancer
Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases
Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic… Read More »Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases
Muthu Alagappan, MD, Medical Director at Notable Health The COVID-19 pandemic has caused an unprecedented shift in the way consumers view and access a variety of goods and services—and healthcare is no exception. Recent studies show that many patients, including vulnerable populations like those living with cancer, are delaying recommended care and… Read More »Virtually or In-Person, Automation Improves The Healthcare Experience
There is a food that offers the best of both worlds—significantly improving our ability to detox carcinogens like diesel fumes and decreasing inflammation in our airways—all while improving our respiratory defenses against infections. Outdoor air pollution may be the ninth leading cause of death and… Read More »Combating Air Pollution Effects with Food
Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics. The companies signed a deal to develop cancer immunotherapies in summer 2017, where Darmstadt-based Merck KGaA paid $115 million up front, agreeing to further payments during the first two years of… Read More »Merck KGaA takes second option from cancer immunotherapy pact with F-Star
What You Should Know: – Digital surgery pioneer Activ Surgical raises $15M in funding led by ARTIS Ventures to accelerate U.S. commercialization and European expansion efforts for its ActiveEdge platform, which enables existing surgical systems, from scopes to robots, to visualize, characterize and track tissue,… Read More »Activ Surgical Raises $15M Advance Autonomous and Collaborative Surgery
Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for patients. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.… Read More »New report explores setbacks that bring future cancer success stories
NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia. In final draft guidance NICE said that the drug is recommended for relapse or refractory FLT3 mutation-positive AML, giving patients an alternative to chemotherapy and its unpleasant side effects. However because of… Read More »NICE backs NHS use for Astellas’ Xospata after rethink
The Oncologic Drugs Advisory Committee voted 12-0 that the benefit-risk profile of belantamab mafodotin supported the drug. The vote came despite concerns expressed by the FDA in briefing documents ahead of the ODAC meeting, particularly with regard to ocular toxicity.
Under the deal, Blueprint will additionally be eligible for more than $900M in milestone payments plus royalties for the RET inhibitor pralsetinib. The deal includes exclusive rights for Roche in ex-U.S. markets other than China and shared rights in the U.S.
What You Should Know: – Paige secures an additional $15M from Goldman Sachs for a total Series B funding round of $70M for its AI-native digital pathology ecosystem. – The company’s continued product portfolio of innovation in telepathology and digital diagnostics accelerated by further investment.… Read More »Paige Lands Additional $15M for AI-Native Digital Pathology Ecosystem
Cumberlege report is a damning reminder of how arrogant, intimidating doctors have suppressed their patients’ views Julia Cumberlege’s report into avoidable harm inflicted by the healthcare system exposes an institutional inability to listen to patients in general and women in particular. Her investigation into decades… Read More »Pelvic mesh scandal is what happens when men with power ignore women | Richard Vize
What You Should Know: – Philips integrates the BioIntelliSense FDA-cleared BioSticker™ sensor as part of its remote patient monitoring solutions for patients outside the hospital. – Multi-parameter sensors aid monitoring across multiple chronic conditions with medical-grade vital signs for physicians to remotely track core symptoms,… Read More »Philips and BioIntelliSense Integrate to Enhance Remote Patient Monitoring
The vast majority of breast cancers start out hormone-dependent, where estradiol, the primary human estrogen, “plays a crucial role in their breast cancer development and progression.” That’s one of the reasons why soy food consumption appears so protective against breast cancer: Soy phytoestrogens, like genistein,… Read More »What Does Drinking Soy Milk Do to Hormone Levels?
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
The patient, who had been enrolled in the Phase I study at the higher dose level of UCARTCS1A, suffered a cardiac arrest, the causes of which are under investigation, the company said.
Do BPA-free plastics such as Tritan, have human hormone-disrupting effects? And what about BPS and BPF? Recent human studies indicate that exposure to the plastics chemical BPA may be associated with infertility, miscarriage, premature delivery, reduced male sexual function, polycystic ovaries, altered thyroid and immune… Read More »Are the BPA-Free Plastics Like Tritan Safe?
I believe Roundup gave me cancer. The Monsanto settlement is a slap in the face | Christine Sheppard
I have to inject myself with needles just to stay alive. Still, Bayer will continue to sell Roundup, and refused to label it as carcinogenic Last Wednesday was my 71st birthday, a low-key celebration in these Covid-19 times. Then I heard the news that the… Read More »I believe Roundup gave me cancer. The Monsanto settlement is a slap in the face | Christine Sheppard
Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications
Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5… Read More »Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we… Read More »Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
What effect do chia seeds have on weight loss, blood sugar, cholesterol, blood pressure, and inflammation? We’ve been eating chia seeds for more than 5,000 years. Historically, they are one of the main crops grown in the Western hemisphere. They are exceptionally high in… Read More »Chia Seeds vs. Flaxseeds
Tea consumption is associated with a reduced risk of heart disease, stroke, and premature death in general, with each additional cup of green tea a day associated with a 4-percent lower mortality risk. So, perhaps “drinking several cups of tea daily can keep the doctor… Read More »Using Green Tea to Help Prevent Cancer and Treat Cancer